Study of Tislelizumab as First Treatment for Advanced Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well Tislelizumab works as the first treatment for advanced non-small cell lung cancer that has spread. It aims to understand which treatment strategies after Tislelizumab lead to the best survival outcomes for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced non-small cell lung cancer that cannot be removed with surgery or has spread to other parts of the body.
- You received Tislelizumab as your first treatment for this advanced cancer.
- Your medical records show that the cancer grew or spread after your first treatment with Tislelizumab.
- You have complete medical records about your cancer stage, type, treatment plan, and follow-up scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This trial tests whether adding the immunotherapy drug tislelizumab before and after surgery can help people with a specific type of lung cancer (non-squamous NSCLC with a KRAS mutation) that is stage 2 or 3. It aims to improve treatment outcomes by targeting the cancer early.
This trial collects information on how well the immunotherapy drug Tislelizumab works for different types of lung cancer. It is meant for people whose doctor already decided to prescribe this drug as part of their care.
This study watches how well Tislelizumab works for people with lung cancer when it is used as part of their normal treatment. It does not give you any new medicine or change your care plan.
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
This trial tests combining the drug tislelizumab with chemotherapy for people with stage III non-small cell lung cancer that hasn't been treated yet. It aims to see if this combination can shrink or control the cancer better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.